SCIENTIFIC PUBLICATIONS
The information contained in each post on this page was factually accurate on the date it was issued and posted.
American Society of Clinical Oncology (ASCO) Virtual Annual Meeting 2021 – STRO-002 – Abstract
To view the abstract on ASCO, click here
Sutro Biopharma Announces Additional Data for Dose-Escalation Phase 1 Study of STRO-002 to be Presented at ASCO 2021
Maturing data from the Phase 1 dose-escalation cohort for STRO-002 showed a median progression-free survival of 7.2 months One patient achieved a CR and nine patients achieved a PR, of which four were confirmed PRs. Median duration of response on the five confirmed...
Sutro Biopharma to Participate in Upcoming Virtual Investor Conferences
SOUTH SAN FRANCISCO, Calif., May 14, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
7th Annual Truist Securities Life Sciences Summit – Presentation
Webcast, Click Here Download Presentation, Click Here
20th Annual Needham Virtual Healthcare Conference – Presentation
Webcast, Click Here Download Presentation, Click Here
Sutro Biopharma to Present at Two Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., April 8, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
Sutro Biopharma Presents at the 11th Annual World ADC Europe 2021 – PowerPoint Presentation
Download the presentation, CLICK HERE
39th Annual JP Morgan Healthcare Conference – Presentation
Webcast, CLICK HERE Download Presentation, CLICK HERE
Sutro Biopharma Presents at the American Society of Hematology (ASH) 2020 – Poster Presentation
Download the Presentation, Click Here
Sutro Biopharma Presents Data from Ongoing Phase 1 Dose-Escalation Study for STRO-001 for the Treatment of B-cell Non-Hodgkin Lymphoma at the 62nd American Society of Hematology Annual Meeting
- STRO-001 was generally well-tolerated in patients with late-line NHL with no ocular or neuropathy toxicity signals; MTD has not been reached - - 1 CR & 2 PRs observed in heavily pretreated patients with DLBCL; 1 SD in marginal zone lymphoma; 2 SDs in follicular...